A Phase Ia, Dose Escalation Study of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab) Injection in Patients With Advanced or Metastatic Solid Tumors.

Trial Profile

A Phase Ia, Dose Escalation Study of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab) Injection in Patients With Advanced or Metastatic Solid Tumors.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Sevacizumab (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 22 Mar 2015 According to the ClinicalTrials.gov record, planned end date changed from 1 Jul 2014 to 1 Nov 2015.
    • 22 Mar 2015 According to the ClinicalTrials.gov record, planned primary completion date changed from 1 Jul 2014 to 1 Nov 2015.
    • 03 May 2013 Status changed from planning to recruiting, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top